

Journal Pre-proof



Time trends in placenta-mediated pregnancy complications after assisted reproductive technology in the Nordic countries

Sindre H. Petersen., Christina Bergh, MD PhD., Mika Gissler, PhD., Bjørn O. Åsvold, MD PhD., Liv B. Romundstad, MD PhD., Aila Tiitinen, MD PhD., Anne L. Spangmose, MD., Anja Pinborg, MD PhD., Ulla-Britt Wennerholm, MD PhD., Anna-Karina A. Henningsen, MD., Signe Opdahl, MD PhD.

PII: S0002-9378(20)30218-0

DOI: <https://doi.org/10.1016/j.ajog.2020.02.030>

Reference: YMOB 13131

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 12 November 2019

Revised Date: 30 January 2020

Accepted Date: 8 February 2020

Please cite this article as: Petersen. SH, Bergh C, Gissler M, Åsvold BO, Romundstad LB, Tiitinen A, Spangmose AL, Pinborg A, Wennerholm U-B, Henningsen A-KA, Opdahl S, Time trends in placenta-mediated pregnancy complications after assisted reproductive technology in the Nordic countries, *American Journal of Obstetrics and Gynecology* (2020), doi: <https://doi.org/10.1016/j.ajog.2020.02.030>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Elsevier Inc. All rights reserved.

Time trends in placenta-mediated pregnancy complications after assisted reproductive technology in the Nordic countries

Authors: Sindre H. PETERSEN.¹; Christina BERGH, MD PhD.²; Mika GISSLER PhD.³; Bjørn O. ÅSVOLD, MD PhD.^{4,5}; Liv B. ROMUNDSTAD, MD PhD.^{6,7}; Aila TIITINEN, MD PhD.⁸; Anne L. SPANGMOSE, MD.⁹; Anja PINBORG, MD PhD.⁹; Ulla-Britt WENNERHOLM, MD PhD.²; Anna-Karina A. HENNINGSEN, MD.⁹ and Signe OPDAHL, MD PhD.¹

¹ Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

² Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden

³ THL Finnish Institute for Health and Welfare, Helsinki, Finland and Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden

⁴ K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

⁵ Department of Endocrinology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

⁶ Spiren Fertility Clinic, Trondheim, Norway

⁷ Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway

⁸ Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

⁹ The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

28 Sources of funding:

29 This work was supported by the Nordic Trial Alliance: a pilot project jointly funded by the
30 Nordic Council of Ministers and NordForsk [grant number 71450], the Central Norway
31 Regional Health Authorities [grant number 46045000], the Nordic Federation of Obstetrics
32 and Gynaecology [grant numbers NF13041, NF15058, NF16026 and NF17043],
33 and by the Research Council of Norway's Centre of Excellence funding scheme [grant
34 number 262700] and the Faculty of Medicine and Health Science, Norwegian University of
35 Science and Technology [grant number 70367047]

36

37 **Conflicts of Interest:** The authors report no conflict of interest.

38

39 **Condensation:** Risk of placenta-mediated pregnancy complications remains higher after
40 assisted reproductive technology, and increases for hypertensive disorders in twin pregnancies
41 and for placenta previa overall.

42

43 **Short title:** Time trends in pregnancy complications after assisted reproductive technology.

44

45 AJOG at a glance

46 Why was this study conducted?

47 Use of assisted reproductive technology (ART) increases worldwide with improving perinatal
48 outcomes. We aimed to investigate changes in occurrence of placenta-mediated complications
49 in ART pregnancies compared to the background population over three decades.

50

51 Key findings

52 ART pregnancies continue to be at higher risk, despite declining rates of multiple
53 pregnancies. Risk of hypertensive disorders in twin pregnancies is increasing regardless of
54 conception method, while risk of placenta previa has increased more strongly in ART
55 pregnancies. Risk of placental abruption risk has decreased in both populations.

56

57 **What does this add to what is known?**

58 Recent improvements in perinatal outcomes after ART have not been accompanied by a
59 corresponding improvement in maternal pregnancy health in this population. Increasing risk
60 of placenta previa requires further attention.

61

62 **Key words:**

63 Preeclampsia, hypertensive disorders in pregnancy, gestational hypertension, placental
64 abruption, placenta previa, assisted reproduction, in vitro fertilization, reproductive medicine,
65 temporal changes, twins.

66

67 **Abstract**

68 **Background:** The use of assisted reproductive technology (ART) is increasing worldwide and
69 conception after assisted reproduction currently comprises 3-6% of birth cohorts in the Nordic
70 countries. The risk of placenta-mediated pregnancy complications is higher after ART
71 compared to spontaneously conceived pregnancies. Whether the excess risk of placenta-
72 mediated pregnancy complications in pregnancies following assisted reproduction has
73 changed over time, is unknown.

74

75 **Objectives:** To investigate whether time trends in risk of pregnancy complications
76 (hypertensive disorders in pregnancy, placental abruption and placenta previa) differ for

77 pregnancies after ART compared to spontaneously conceived pregnancies during three
78 decades of assisted reproduction treatment in the Nordic countries.

79

80 Study Design: In a population-based cohort study, with data from national health registries in
81 Denmark (1994-2014), Finland (1990-2014), Norway (1988-2015) and Sweden (1988-2015),
82 we included 6,830,578 pregnancies resulting in delivery. Among these, 146,998 (2.2%) were
83 pregnancies after assisted reproduction (125,708 singleton pregnancies, 20,668 twin
84 pregnancies and 622 of higher order plurality) and 6,683,132 (97.8%) pregnancies were
85 conceived spontaneously (6,595,185 singleton pregnancies, 87,106 twin pregnancies and
86 1,289 of higher order plurality). We used logistic regression with post-estimation to estimate
87 absolute risks and risk differences for each complication. We repeated analyses for singleton
88 and twin pregnancies, separately. In sub-samples with available information, we also adjusted
89 for maternal body mass index, smoking during pregnancy, previous cesarean section, culture
90 duration and cryopreservation.

91

92 Results: The risk of each placental complication was consistently higher in pregnancies
93 following ART compared to spontaneously conceived pregnancies across the study period,
94 except for hypertensive disorders in twin pregnancies, where risks were similar. Risk of
95 hypertensive disorders increased over time in twin pregnancies for both conception methods,
96 but more strongly for pregnancies following ART (risk difference 1.73 percentage points per
97 5 years, 95% confidence interval 1.35 to 2.11) than for spontaneously conceived twins (risk
98 difference 0.75 percentage points, 95% confidence interval 0.61 to 0.89). No clear time trends
99 were found for hypertensive disorders in singleton pregnancies. Risk of placental abruption
100 decreased over time in all groups (risk difference -0.16 percentage points, 95% confidence
101 interval -0.19 to -0.12 and -0.06 percentage points, 95% confidence interval -0.06 to -0.05 for

102 pregnancies after assisted reproduction and spontaneously conceived pregnancies,
103 respectively, for singletons and multiple pregnancies combined). Over time, the risk of
104 placenta previa increased in pregnancies after assisted reproduction among both singletons
105 (risk difference 0.21 percentage points, 95% confidence interval 0.14 to 0.27) and twins (risk
106 difference 0.30 percentage points, 95% confidence interval 0.16 to 0.43), but remained stable
107 in spontaneously conceived pregnancies. When adjusting for culture duration, the temporal
108 increase in placenta previa became weaker in all groups of ART pregnancies, whereas
109 adjustment for cryopreservation moderately attenuated trends in ART twin pregnancies.

110

111 Conclusions: The risk of placenta-mediated pregnancy complications following ART remains
112 higher compared to spontaneously conceived pregnancies, despite declining rates of multiple
113 pregnancies. For hypertensive disorders in pregnancy and placental abruption, pregnancies
114 after assisted reproduction follow the same time trends as the background population, whereas
115 for placenta previa, risk has increased over time in pregnancies after ART.

116

117

118

119 Introduction

120 Assisted reproductive technology (ART) comprises conception methods where fertilization
121 takes place outside the female body. Risk of placenta-mediated pregnancy complications,
122 including preeclampsia, placental abruption and placenta previa, is higher in pregnancies after
123 ART treatment compared to spontaneously conceived (SC) pregnancies^{1,2}. Risk of adverse
124 perinatal outcomes such as preterm birth, low birthweight and perinatal death is also higher^{3,4}.
125 This has been attributed partly to the high occurrence of multiple pregnancies after ART
126 treatment. Still, singleton ART pregnancies also carry a higher risk of adverse outcomes

127 compared to SC singletons^{1,2}. The underlying causes of infertility, as well as the ART
128 treatment itself, may both contribute to the higher risk⁵⁻⁸. It has been hypothesized that the
129 super-physiological hormone levels seen in ART-cycles may alter early placentation and
130 thereby contribute to adverse outcomes⁹.

131

132 Worldwide, ART treatment has increased steadily over the past decades, due to increasing
133 availability and success rates in combination with sociodemographic changes with
134 postponement of childbearing¹⁰. Simultaneously, perinatal outcomes after ART conception
135 have improved and are approaching the levels of the background population, mainly due to
136 reduction of multiple births, but also due to the improved health in ART singletons¹¹.

137

138 It seems likely that the increasing use and success rates of ART would be accompanied by
139 changes in the population of women seeking medical attention for infertility. Women treated
140 with ART today comprise a larger proportion of the total population and may therefore be
141 more comparable to the background population than women treated some decades ago.

142 Conversely, advances in ART¹² over time may also have enabled more severely infertile
143 women to become pregnant. Previous studies indicate that risk of some placenta-mediated
144 pregnancy complications, namely preeclampsia and placental abruption, is declining in the
145 general population^{13,14}. Whether this development also concerns ART pregnancies is
146 unknown.

147

148 The objective of this study was to investigate whether time trends in occurrence of placenta-
149 mediated pregnancy complications; hypertensive disorders in pregnancy (HDP), placental
150 abruption and placenta previa, differ for ART pregnancies compared to SC pregnancies
151 during three decades of ART treatment in the Nordic countries.

152

153 Material and Methods

154

155 Study population and data sources

156

157 The Committee of Nordic ART and Safety (CoNARTaS) study population comprises all
158 deliveries in Denmark (1994–2014), Finland (1990–2014), Norway (1984–2015) and Sweden
159 (1985–2015). Data were obtained from the nationwide Medical Birth Registries (MBRs) in
160 each country, where detailed information on maternal, fetal and neonatal health for all
161 deliveries is recorded. Individual level data from MBRs can be linked to other data sources
162 through the unique national identity number assigned to all residents in the Nordic
163 countries¹⁵. ART conception was determined through direct reporting to MBRs (Finland
164 1990–2014, Norway 1984–2015 and Sweden 1985–2006), in separate notifications of all ART
165 pregnancies at gestational week 6-7 (Norway 1984–2015) or through linkage with cycle-based
166 ART registries (Denmark 1994–2014 and Sweden 2007–2015).

167 From the MBRs we obtained information on birth year, plurality, birthweight,
168 gestational age, offspring sex, parity, maternal age, smoking status in pregnancy and body
169 mass index (BMI, measured pre-pregnancy or in first trimester). For SC pregnancies,
170 gestational age was estimated based on ultrasound examination or on last menstrual period if
171 information from ultrasound examination was unavailable. For ART pregnancies, gestational
172 age was estimated based on ultrasound examination or on date of embryo transfer and culture
173 duration, according to clinical practice in each country.

174 Information on pregnancy complications was obtained directly from MBRs in Finland
175 (2004–2014), Norway (1984–2015) and Sweden (1985–2015) and from data linkage with
176 national patient registries (NPRs) in Denmark (1994–2014) and Finland (1989–2014). In the
177 MBRs, complications are reported at delivery with limited information on gestational age at
178 diagnosis. In Norway, the MBR revised the notification form in 1998, changing the reporting
179 of pregnancy complications from free text to checkboxes. For NPR data, diagnoses from each
180 prenatal visit, delivery and postpartum controls were linked to each pregnancy using maternal
181 identity and date of delivery. The Danish NPR comprised data from hospital admissions and
182 outpatient visits in public specialist health care during the entire study period, and from
183 private specialist health care since 2003. The Finnish NPR expanded its data collection in
184 1998 from hospital admissions only to include also hospital outpatient visits.

185

186 Because there were very few ART deliveries during the first years of registration, and among
187 women of young or high reproductive ages, we restricted the study to 1988–2015 and
188 deliveries with maternal age 22–44 years. Thus, a total of 6,830,578 deliveries among
189 4,160,402 women were eligible.

190 We excluded 120,628 deliveries with missing information on one or more study
191 variables and 12,944 deliveries with gestational age <22 or ≥ 45 weeks, birthweight <300 g or
192 ≥ 6000 g and birthweight for gestational age $\geq +6$ standard deviations¹⁶. Multiple pregnancies
193 were excluded when at least one child met the exclusion criteria. Our main analysis sample
194 included 146,998 deliveries after ART and 6,683,580 deliveries of SC pregnancies. Selection
195 of the study population and sub-samples for sensitivity analyses are described in Figure 1.

196

197 Outcome variables

198 Pregnancy complications were registered according to national adaptations of the
199 International Classification of Diseases and related Health Problems (ICD) classification as
200 outlined in Supplemental Table 1.

201

202 We considered HDP as a combined outcome including preeclampsia, eclampsia, gestational
203 hypertension, and chronic hypertension with superimposed preeclampsia. We did not consider
204 chronic hypertension as a hypertensive disorder in pregnancy because pre-pregnancy
205 conditions cannot be a consequence of ART. For MBR data, any reporting of relevant ICD
206 codes were considered as events, whereas the following diagnoses were included from NPRs:
207 Diagnoses of HDP registered after 20 weeks gestation, any diagnosis of placental abruption,
208 and any diagnosis of placenta previa in the third trimester or within one month before
209 delivery.

210

211 Statistical analyses

212 We used logistic regression to estimate time trends in occurrence of pregnancy complications
213 within the ART and SC populations. To facilitate interpretation, we used post-estimation
214 commands to calculate absolute risks and risk differences (RDs) with 95% confidence
215 intervals (CIs). We estimated trends over birth year categories (1988-1992, 1993-1997, 1998-
216 2002, 2003-2007, 2008-2012, 2013-2015) and as linear trends across the study period (change
217 per 5 years, continuous variable). We also compared risk of each complication in ART versus
218 SC pregnancies within each period as a measure of whether risks in the two populations
219 converged over time. Analyses were performed on the all pregnancies, and for singletons and
220 twins, separately. We adjusted for parity, maternal age and country. To investigate whether
221 time trends differed between countries, we repeated analyses for each country separately.

222 We performed several sensitivity analyses to investigate potential explanations for the
223 observed trends: We repeated analyses for primiparous women. In sub-samples with available
224 information, we adjusted for maternal BMI and smoking. Within the ART population, we also
225 adjusted for embryo cryopreservation (restricted to Denmark, Norway and Sweden) and
226 culture duration (cleavage stage 2-3 days vs blastocyst stage 5-6 days, restricted to Denmark
227 and Sweden). Next, we restricted diagnosis of placenta previa to pregnancies with delivery by
228 cesarean section, which is required in cases of complete obstruction. Furthermore, to
229 investigate the potential impact of a previous cesarean section, a known risk factor for
230 placenta previa subjected to marked time trends, we adjusted for this in a sub-sample of
231 deliveries among parous women whose first delivery was included in the study. Statistical
232 analyses were performed using Stata/MP for Windows, Version 15.0 (StataCorp LLC,
233 College Station, Texas, USA).

234

235 Ethical considerations and approvals

236 Approvals for data retrieval and linkage were obtained in each country. In Denmark and
237 Finland, ethical approval is not required for research solely based on registry data. In Norway,
238 ethical approval was given by the Regional Committee for Medical and Health Research
239 Ethics (REC North, 2010/1909). In Sweden approval was obtained from the Ethical
240 committee in Gothenburg, Dnr 214-12, T422-12, T516-15, T233-16, T300-17, T1144-17,
241 T121-18.

242

243 Results

244 For the total period, deliveries after ART constituted 3.0% of birth cohorts in Denmark, 1.8%
245 in Finland, 2.0% in Norway and 2.0% in Sweden (Table 1). There was a clear increase in

246 ART deliveries over time from 0.8% of all deliveries in 1988-1997 to 3.4% in 2008-2015,
247 accompanied by a reduction of multiple pregnancies in ART from 26% in 1988-1997 to 8.7%
248 in 2008-2015. The proportion of SC multiple pregnancies remained stable around 1.3%.

249 Overall, parity was lower (68.0% versus 39.5% primiparous) and mean maternal age
250 higher (33.8 versus 30.3 years) in ART compared to SC pregnancies, whereas BMI was
251 similar between the two groups. ART mothers smoked less (5.7%) than spontaneously
252 conceiving mothers (11.8%). Cesarean sections (30.9% versus 15.4%) and labor inductions
253 (20.7% versus 13.4%) were more common in ART compared to SC pregnancies.

254

255 Hypertensive disorders in pregnancy

256 Risk of HDP in SC pregnancies was 4.4% (Table 2). For all pregnancies (i.e. singletons and
257 multiples combined), risk of HDP was higher in ART compared to SC pregnancies
258 throughout the study period (odds ratio [OR] 1.25, 95% CI 1.23 to 1.28, corresponding to a
259 RD of 1.06 percentage points [*pp*]). In SC pregnancies, risk increased with 0.17 *pp* per 5
260 years (95% CI 0.16 to 0.18). The increase was stronger in twin compared to singleton
261 pregnancies (RD 0.75 and 0.16 *pp* per 5 years, respectively). When adjusting for maternal
262 smoking and BMI in a sub-sample, time trends were reversed in SC singletons and
263 substantially attenuated in SC twins (Supplemental Table 2). For all ART pregnancies
264 combined, there was no clear time trend. However, in separate analyses of singleton and twin
265 pregnancies, development followed that in SC pregnancies (Figures 2A and 2B), with
266 strongly increasing risk in twin pregnancies (RD 1.73 *pp* per 5 years, 95% CI 1.35 to 2.11) in
267 all countries. Adjustment for maternal smoking and BMI had little influence on trends in ART
268 pregnancies, but adjustment for cryopreservation moderately attenuated trends in ART twin
269 pregnancies (Supplemental Table 2).

270

271 Placental abruption

272 Risk of placental abruption in SC pregnancies was 0.43% (Table 3). Throughout the study
273 period, risk of placental abruption was consistently higher in ART compared to SC
274 pregnancies, both overall (OR 1.95 across the study period, 95% CI 1.83 to 2.07,
275 corresponding to a RD of 0.40 *pp*) and when separating singleton and twin pregnancies. Risk
276 of placental abruption decreased weakly over time in SC pregnancies (RD -0.06 *pp* per 5
277 years, 95% CI -0.06 to -0.05), with similar trends for singleton and twin pregnancies. In ART
278 pregnancies, the risk decrease was somewhat stronger than in SC pregnancies (RD -0.16 *pp*
279 per 5 years, 95% CI -0.19 to -0.12) and of similar magnitude in singletons and twins. Country
280 specific analyses were compatible with results from pooled analyses (Figures 2C and 2D). In
281 all groups, time trends remained broadly similar after additional adjustment for BMI and
282 smoking (Supplemental Table 3).

283

284 Placenta previa

285 Risk of placenta previa in SC pregnancies was 0.34% (Table 4). Placenta previa was
286 considerably more common in ART compared to SC pregnancies across the study period for
287 all pregnancies combined (OR 3.87, 95% CI 3.70 to 4.04 corresponding to a RD of 0.95 *pp*),
288 and for singleton and twin pregnancies separately. In SC pregnancies, risks did not
289 substantially differ between singletons and twins, whereas for ART pregnancies, risk was
290 somewhat higher for singletons than for twins. In SC pregnancies, risk increased weakly over
291 time for singleton pregnancies (RD 0.03 *pp* per 5 years) but remained stable for twins (Figure
292 2E). In contrast, risk increased strongly with time in ART pregnancies (RD 0.24 *pp* per 5
293 years for all pluralities combined, 95% CI 0.18 to 0.30). Trends in ART pregnancies were
294 similar for singletons and twins and were most pronounced in Denmark and Finland (Figure
295 2F).

296 In sensitivity analyses, results remained similar when adjusting for smoking and BMI
297 (Supplemental Table 4), when restricting analyses to primiparous women, when restricting
298 diagnoses of placenta previa to those accompanied by cesarean section, and when adjusting
299 for previous cesarean section. When adjusting for culture duration, the temporal increase in
300 placenta previa became weaker in all groups of ART pregnancies.

301

302 Comment

303 **Main findings**

304 In this registry-based cohort with nationwide data from four countries across almost three
305 decades, we found a higher risk of placenta-mediated pregnancy complications in ART
306 pregnancies compared to the background population of SC children throughout the study
307 period. For placenta previa, risk increased substantially over time in ART pregnancies, in
308 contrast to a weakly increasing risk in the background population. For HDP, ART
309 pregnancies followed the trends of the background population, with weakly increasing
310 occurrence in singletons and strongly increasing occurrence in twins. Risk of placental
311 abruption decreased over time in all groups.

312

313 **Results**

314 Recent meta-analyses of observational studies show positive associations between ART
315 conception and gestational hypertension, preeclampsia, placental abruption and placenta
316 previa^{1,17}. Our results are largely consistent with these studies, apart from lower risk of HDP
317 in ART twin pregnancies compared to SC twin pregnancies.

318

319 We are not aware of previous studies investigating time trends in pregnancy complications
320 following ART conception. However, some studies of time trends in the general population

321 exist for these complications. In contrast to the weakly increasing rates of HDP in the general
322 population that we observed from 1988 to 2015, Roberts et al.¹⁴ reported declining rates of
323 gestational hypertension and preeclampsia in several Western populations, including
324 Denmark, Norway and Sweden, during the shorter time span from 1997 to 2007. Causes of
325 the increasing incidence of HDP in twin pregnancies are unknown, but are not likely due to
326 increasing gestational age, since mean gestational age did not increase in twin pregnancies
327 across time in our study, in line with the previously reported stable occurrence of preterm
328 birth for twin pregnancies¹¹.

329
330 Ananth et al.¹³ reported declining rates of placental abruption in singleton pregnancies in
331 several Western populations, including the Nordic countries, from 1978 to 2008. They
332 hypothesized that this might be due to changes in smoking. Our results are consistent with
333 their study, but additionally show that risk of placental abruption has declined regardless of
334 conception methods and multiplicity, suggesting that the development might be driven by
335 reduction in risk factors common to all subgroups. However, smoking seemed not to explain
336 this development, since adjustment for smoking had very little influence on trends, both for
337 ART and SC pregnancies.

338
339 An Australian cohort study showed that the risk of placenta previa in the general population
340 increased from 0.69% to 0.87% in the years 2001–2009¹⁸, while a Swiss population-based
341 cohort study showed an increase in the yearly incidence of placenta previa from 0.3% to 0.5%
342 between 1993 and 2014¹⁹. Although our results support an overall increasing trend, the
343 increase of placenta previa in the background population was much weaker. The increase in
344 risk in ART pregnancies was considerably stronger, a finding not previously reported.
345 Consistent with expectations from a Swedish study showing higher risk of placenta previa

346 after blastocyst transfer²⁰ in a sub-sample of our Swedish study population, the increasing risk
347 of placenta previa over time attenuated moderately after adjustment for culture duration.

348

349 **Clinical implications**

350 When considering all ART pregnancies combined, risk of all complications declined
351 considerably and approached that in the background population during the study period,
352 mainly due to declining occurrence of multiple pregnancies, a major risk factor for adverse
353 outcomes, after ART conception. Elective single embryo transfer (eSET) policies in the
354 Nordic countries have led to substantial reductions in multiple pregnancies after ART, thereby
355 also reducing risk of adverse outcomes in ART pregnancies. Thus, our results further
356 emphasize the importance of eSET.

357

358 The increasing risk of placenta previa in ART pregnancies is a matter of concern and could
359 only partly be explained by the concurrent increase in blastocyst culture. Whether other
360 treatment-related and thus potentially modifiable factors are involved, or whether changes in
361 characteristics of the ART population contribute to this trend, is not yet known.

362

363 Furthermore, informing clinicians and infertile couples that ART pregnancies are still at
364 higher risk of placenta-mediated pregnancy complications despite increasing success rates and
365 improving neonatal outcomes in ART^{11,21}, is important.

366

367

368 **Research implications**

369 Future studies should investigate underlying causes for the increasing occurrence of HDP in
370 twin pregnancies. In addition, reasons behind the increasing incidence of placenta previa in
371 ART pregnancies warrant further investigation.

372

373 **Strengths and limitations**

374 A key strength of this study is the large study sample with data on all deliveries in four
375 Nordic countries over three decades, which enabled precisely estimated time trends in most
376 analyses. Nonetheless, there were few events in the ART population in the earliest study
377 period and that power was limited also in some sensitivity analyses.

378

379 Another strength is that we could adjust for potential confounders such as parity, maternal age
380 and country, as well as BMI, smoking and cesarean section in subsamples. Still, we cannot
381 exclude residual confounding by unmeasured factors such as causes for infertility or from
382 misclassification of self-reported information such as smoking status.

383

384 In the Nordic countries, ART treatment is strongly subsidized, ensuring that the couple's
385 financial situation is not a major determinant of ART conception. In combination with
386 nationwide data sources with a very low proportion of missing data, this suggests that
387 selection bias should be minimal. Furthermore, practically all pregnant women attend the
388 publicly financed antenatal care program. In consequence, opportunities to detect pregnancy
389 complications should not differ between the two conception methods, and the overall validity
390 of such diagnoses is acceptable in all countries²²⁻²⁶. However, it is possible that women who
391 conceive through ART have a lower threshold for seeking medical attention during
392 pregnancy, and detection bias thus cannot be excluded.

393 Occurrence of pregnancy complications was generally higher when extracted from
394 patient registries (Denmark, Finland) than from MBRs only (Norway, Sweden). Changes in
395 registration and coding practice over time may also have influenced the observed trends but
396 should not affect ART and SC pregnancies differently.

397

398

399 **Conclusions**

400 Risk of placenta-mediated pregnancy complications following ART conception is higher than
401 for SC pregnancies in the Nordic countries. For HDP and placental abruption, ART
402 pregnancies follow the same trends as the background population. Risk of HDP is increasing
403 in both ART and SC twin pregnancies. Placenta previa risk has increased strongly over time
404 in ART pregnancies.

405

406 **References**

407

- 408 1. Qin J, Wang H, Sheng X, Liang D, Tan H, Xia J. Pregnancy-
409 related complications and adverse pregnancy outcomes in
410 multiple pregnancies resulting from assisted reproductive
411 technology: a meta-analysis of cohort studies. *Fertility and
412 sterility*. 2015;103(6):1492-1508.e1491-1497.
- 413 2. Qin J, Liu X, Sheng X, Wang H, Gao S. Assisted reproductive
414 technology and the risk of pregnancy-related complications
415 and adverse pregnancy outcomes in singleton pregnancies: a
416 meta-analysis of cohort studies. *Fertility and sterility*.
417 2016;105(1):73-85.e71-76.
- 418 3. Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal
419 outcomes in singletons following in vitro fertilization: a

- 420 meta-analysis. *Obstetrics and gynecology*. 2004;103(3):551-
421 563.
- 422 4. Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari
423 A. Obstetric and perinatal outcomes in singleton pregnancies
424 resulting from IVF/ICSI: a systematic review and meta-
425 analysis. *Human reproduction update*. 2012;18(5):485-503.
- 426 5. Berntsen S, Soderstrom-Anttila V, Wennerholm UB, et al. The
427 health of children conceived by ART: 'the chicken or the
428 egg?'. *Hum Reprod Update*. 2019;25(2):137-158.
- 429 6. Henningsen AK, Pinborg A, Lidegaard O, Vestergaard C,
430 Forman JL, Andersen AN. Perinatal outcome of singleton
431 siblings born after assisted reproductive technology and
432 spontaneous conception: Danish national sibling-cohort
433 study. *Fertil Steril*. 2011;95(3):959-963.
- 434 7. Opdahl S, Henningsen AA, Tiitinen A, et al. Risk of
435 hypertensive disorders in pregnancies following assisted
436 reproductive technology: a cohort study from the CoNARTaS
437 group. *Hum Reprod*. 2015;30(7):1724-1731.
- 438 8. Romundstad LB, Romundstad PR, Sunde A, et al. Effects of
439 technology or maternal factors on perinatal outcome after
440 assisted fertilisation: a population-based cohort study.
441 *Lancet*. 2008;372(9640):737-743.
- 442 9. Vermey BG, Buchanan A, Chambers GM, et al. Are singleton
443 pregnancies after assisted reproduction technology (ART)
444 associated with a higher risk of placental anomalies
445 compared with non-ART singleton pregnancies? A
446 systematic review and meta-analysis. *Bjog*.
447 2019;126(2):209-218.
- 448 10. Schmidt L, Sobotka T, Bentzen JG, Nyboe Andersen A.
449 Demographic and medical consequences of the
450 postponement of parenthood. *Hum Reprod Update*.
451 2012;18(1):29-43.
- 452 11. Henningsen AA, Gissler M, Skjaerven R, et al. Trends in
453 perinatal health after assisted reproduction: a Nordic study
454 from the CoNARTaS group. *Hum Reprod*. 2015;30(3):710-
455 716.

- 456 12. Farquhar C, Marjoribanks J. Assisted reproductive
457 technology: an overview of Cochrane Reviews. *Cochrane*
458 *Database Syst Rev.* 2018;8:Cd010537.
- 459 13. Ananth CV, Keyes KM, Hamilton A, et al. An international
460 contrast of rates of placental abruption: an age-period-
461 cohort analysis. *PLoS One.* 2015;10(5):e0125246.
- 462 14. Roberts CL, Ford JB, Algert CS, et al. Population-based trends
463 in pregnancy hypertension and pre-eclampsia: an
464 international comparative study. *BMJ Open.*
465 2011;1(1):e000101.
- 466 15. Opdahl S, Henningsen AA, Bergh C, et al. Data resource
467 profile: the Committee of Nordic Assisted Reproductive
468 Technology and Safety (CoNARTaS) cohort. *Int J Epidemiol.*
469 2019.
- 470 16. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B.
471 Intrauterine growth curves based on ultrasonically
472 estimated foetal weights. *Acta Paediatr.* 1996;85(7):843-848.
- 473 17. Almasi-Hashiani A, Omani-Samani R, Mohammadi M, et al.
474 Assisted reproductive technology and the risk of
475 preeclampsia: an updated systematic review and meta-
476 analysis. *BMC Pregnancy Childbirth.* 2019;19(1):149.
- 477 18. Roberts CL, Algert CS, Warrendorf J, Olive EC, Morris JM,
478 Ford JB. Trends and recurrence of placenta praevia: a
479 population-based study. *Aust N Z J Obstet Gynaecol.*
480 2012;52(5):483-486.
- 481 19. Kaelin Agten A, Passweg D, von Orelli S, Ringel N, Tschudi R,
482 Tutschek B. Temporal trends of postpartum haemorrhage in
483 Switzerland: a 22-year retrospective population-based
484 cohort study. *Swiss Med Wkly.* 2017;147:w14551.
- 485 20. Ginstrom Ernstad E, Bergh C, Khatibi A, et al. Neonatal and
486 maternal outcome after blastocyst transfer: a population-
487 based registry study. *American journal of obstetrics and*
488 *gynecology.* 2016;214(3):378.e371-378.e310.
- 489 21. De Geyter C, Calhaz-Jorge C, Kupka MS, et al. ART in Europe,
490 2014: results generated from European registries by ESHRE:
491 The European IVF-monitoring Consortium (EIM) for the

- 492 European Society of Human Reproduction and Embryology
 493 (ESHRE). *Hum Reprod.* 2018;33(9):1586-1601.
- 494 22. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V,
 495 Pedersen L, Sorensen HT. The Danish National Patient
 496 Registry: a review of content, data quality, and research
 497 potential. *Clin Epidemiol.* 2015;7:449-490.
- 498 23. Sund R. Quality of the Finnish Hospital Discharge Register: a
 499 systematic review. *Scand J Public Health.* 2012;40(6):505-
 500 515.
- 501 24. Thomsen LC, Klungsoyr K, Roten LT, et al. Validity of the
 502 diagnosis of pre-eclampsia in the Medical Birth Registry of
 503 Norway. *Acta Obstet Gynecol Scand.* 2013;92(8):943-950.
- 504 25. Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors
 505 for preeclampsia and gestational hypertension in a
 506 population-based cohort study. *Am J Epidemiol.*
 507 1998;147(11):1062-1070.
- 508 26. Klungsoyr K, Harmon QE, Skard LB, et al. Validity of pre-
 509 eclampsia registration in the medical birth registry of
 510 norway for women participating in the norwegian mother
 511 and child cohort study, 1999-2010. *Paediatr Perinat*
 512 *Epidemiol.* 2014;28(5):362-371.

513

514 **Figure captions:**

- 515 • **FIGURE 1: Selection of the study population and sub-samples for sensitivity**
 516 **analyses.** *ART*, assisted reproductive technology, *SC*, spontaneous conception, *BMI*,
 517 body mass index. Solid line arrows pointing to the right indicate exclusions, dashed
 518 line arrows pointing to the right indicate sub-sample selection.
- 519 • **FIGURE 2: Time trends in risk if placenta-mediated pregnancy complications**
 520 **according to conception method, plurality and country.** *ART*, assisted reproductive
 521 technology, *HDP*, hypertensive disorders in pregnancy. Estimates are adjusted for
 522 parity and maternal age.

523

524 ^aUsing z-scores from Marsal et. al where the authors developed growth curves

525 based on ultrasonography from Swedish centers and made exclusive curves

526 according to offspring sex

527 ^bDeliveries among parous women whose first delivery was included in the main


528 analysis sample and thus had information on delivery mode in all previous


529 deliveries

530 ^cData from Denmark (2011-2014), Norway (2011-2015) and Sweden (2006-2015)

531 ^dData from Denmark (1994-2014), Norway (1988-2015) and Sweden (1988-2015)

532





Supplemental Table 1. Overview of coding systems in use in the Nordic countries during the study period and selection of codes from each system.

		International Classification of Diseases and related Health Problems (ICD) classification version		
		ICD-8	ICD-9	ICD-10
Year in use				
	Denmark	-	-	1994-2014
	Finland	-	1989-1995	1996-2014
	Norway	1988-1998	-	1999-2015
	Sweden	-	1988-1996	1997-2015
Diagnostic codes				
	Hypertensive disorders in pregnancy	637	642.3-7	O11, 013-16
	Placental abruption	632.1	641.2	O45
	Placenta previa	632.0	641.0, 641.1	O44

Supplemental Table 2. Time trends in hypertensive disorders in pregnancies conceived after assisted reproductive technology (ART) and spontaneous conception. Estimates of time trends are risk differences in percentage points.

Analysis sample	Model	Cases/ Deliveries	RD ^a (95% CI)	Cases/ Deliveries	RD ^a (95% CI)
All pregnancies		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		-0.26 (-0.44 to -0.08)		0.06 (0.04 to 0.08)
B) BMI & smoking	Basic model ^b + smoking ^c	6,928/ 93,295	-0.27 (-0.45 to -0.09)	149,946/ 3,424,972	0.03 (0.01 to 0.05)
B) BMI & smoking	Basic model ^b + BMI ^d		-0.29 (-0.46 to -0.11)		-0.10 (-0.12 to -0.08)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		-0.31 (-0.49 to -0.13)		-0.13 (-0.15 to -0.11)
C) Primiparous	Basic model ^e	8,979/ 99,974	-0.02 (-0.15 to 0.12)	172,609/ 2,641,775	0.29 (0.27 to 0.31)
E) Culture duration	Basic model ^b	3,658/ 53,230	0.04 (-0.05 to 0.13)		
E) Culture duration	Basic model ^b + culture duration ^f		0.00 (-0.09 to 0.10)		
F) Cryopreservation	Basic model ^b	8,737/ 121,987	-0.03 (-0.05 to -0.03)		
F) Cryopreservation	Basic model ^b + cryopreservation ^g		-0.05 (-0.08 to -0.03)		
Singletons		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		0.07 (-0.18 to 0.25)		0.05 (0.03 to 0.07)
B) BMI & smoking	Basic model ^b + smoking ^c	5,401/ 82,867	0.07 (-0.11 to 0.26)	144,510/ 3,380,732	0.03 (0.01 to 0.04)
B) BMI & smoking	Basic model ^b + BMI ^d		0.05 (-0.14 to 0.23)		-0.10 (-0.12 to -0.09)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		0.03 (-0.15 to 0.22)		-0.14 (-0.16 to -0.12)
C) Primiparous	Basic model ^e	6,578/ 85,404	0.23 (0.09 to 0.37)	166,549/ 2,607,276	0.28 (0.26 to 0.30)
E) Culture duration	Basic model ^b	3,019/ 49,285	0.07 (-0.02 to 0.16)		
E) Culture duration	Basic model ^b + culture duration ^f		0.05 (-0.04 to 0.14)		
F) Cryopreservation	Basic model ^b	6,349/ 104,085	0.02 (0.00 to 0.04)		
F) Cryopreservation	Basic model ^b + cryopreservation ^g		0.00 (-0.03 to 0.02)		
Twins		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		1.52 (0.83 to 2.22)		0.50 (0.24 to 0.75)
B) BMI & smoking	Basic model ^b + smoking ^c	1,496/ 10,240	1.47 (0.76 to 2.17)	5,375/ 43,690	0.41 (0.15 to 0.67)
B) BMI & smoking	Basic model ^b + BMI ^d		1.46 (0.76 to 2.16)		0.29 (0.03 to 0.55)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		1.39 (0.68 to 2.10)		0.19 (-0.07 to 0.45)
C) Primiparous	Basic model ^e	2,340/ 14,093	1.95 (1.46 to 2.43)	5,963/ 33,856	1.19 (0.92 to 1.46)
E) Culture duration	Basic model ^b	632/ 3,896	0.03 (-0.51 to 0.58)		
E) Culture duration	Basic model ^b + culture duration ^f		-0.14 (-0.69 to 0.41)		
F) Cryopreservation	Basic model ^b	2,334/ 17,164	0.30 (0.21 to 0.38)		
F) Cryopreservation	Basic model ^b + cryopreservation ^g		0.23 (0.14 to 0.31)		

^aPer 5 years in sample B-D and per year in sample E-F. ^bBasic model includes adjustment for parity, maternal age and country. ^cSmoking (yes/no) ^dBMI: <20, 20-24, 25-29, ≥30 kg/m². ^eAdjusted for maternal age and country. ^fCleavage stage vs blastocyst transfer. ^gFresh vs frozen embryo transfer. ART: Assisted reproductive technology, RD: Risk difference, CI: Confidence interval, BMI: Body mass index.

Supplemental Table 3. Time trends in placental abruption in pregnancies conceived after assisted reproductive technology (ART) and spontaneous conception. Estimates of time trends are risk differences in percentage points.

Analysis sample	Model	Cases/ Deliveries	RD ^a (95% CI)	Cases/ Deliveries	RD ^a (95% CI)
All pregnancies		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		-0.11 (-0.16 to -0.05)		-0.02 (-0.03 to -0.02)
B) BMI & smoking	Basic model ^b + smoking ^c	683/ 93,295	-0.10 (-0.15 to -0.04)	12,454/ 3,424,972	-0.01 (-0.02 to -0.00)
B) BMI & smoking	Basic model ^b + BMI ^d		-0.11 (-0.16 to -0.05)		-0.02 (-0.03 to -0.02)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		-0.10 (-0.15 to -0.05)		-0.01 (-0.02 to -0.00)
C) Primiparous	Basic model ^e	816/ 99,974	-0.14 (-0.18 to -0.10)	11,079/ 2,641,775	-0.06 (-0.06 to -0.05)
E) Culture duration	Basic model ^b	384/ 53,230	-0.05 (-0.08 to -0.02)		
E) Culture duration	Basic model ^b + culture duration ^f		-0.05 (-0.09 to -0.02)		
F) Cryopreservation	Basic model ^b	1,073/ 121,987	-0.04 (-0.04 to -0.03)		
F) Cryopreservation	Basic model ^b + cryopreservation ^g		-0.03 (-0.04 to -0.02)		
Singletons		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		-0.07 (-0.12 to -0.02)		-0.02 (-0.03 to -0.02)
B) BMI & smoking	Basic model ^b + smoking ^c	532/ 82,867	-0.06 (-0.11 to -0.00)	12,046/ 3,380,732	-0.01 (-0.02 to -0.01)
B) BMI & smoking	Basic model ^b + BMI ^d		-0.07 (-0.12 to -0.02)		-0.02 (-0.03 to -0.02)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		-0.06 (-0.11 to -0.00)		-0.01 (-0.02 to -0.01)
C) Primiparous	Basic model ^e	592/ 85,404	-0.11 (-0.15 to -0.06)	10,779/ 2,607,276	-0.06 (-0.06 to -0.05)
E) Culture duration	Basic model ^b	317/ 49,282	-0.04 (-0.07 to -0.01)		
E) Culture duration	Basic model ^b + culture duration ^f		-0.05 (-0.08 to -0.02)		
F) Cryopreservation	Basic model ^b	763/ 104,085	-0.02 (-0.03 to -0.02)		
F) Cryopreservation	Basic model ^b + cryopreservation ^g		-0.02 (-0.03 to -0.02)		
Twins		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		-0.07 (-0.31 to 0.17)		-0.05 (-0.12 to 0.02)
B) BMI & smoking	Basic model ^b + smoking ^c	149/ 10,240	-0.07 (-0.31 to 0.17)	405/ 43,690	-0.04 (-0.11 to 0.03)
B) BMI & smoking	Basic model ^b + BMI ^d		-0.07 (-0.31 to 0.17)		-0.06 (-0.13 to 0.01)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		-0.07 (-0.32 to 0.17)		-0.05 (-0.12 to 0.02)
C) Primiparous	Basic model ^e	217/ 14,093	-0.07 (-0.24 to 0.10)	293/ 33,856	-0.03 (-0.10 to 0.04)
E) Culture duration	Basic model ^b	66/ 3,896	-0.15 (-0.35 to 0.05)		
E) Culture duration	Basic model ^b + culture duration ^f		-0.13 (-0.33 to 0.01)		
F) Cryopreservation	Basic model ^b	303/ 17,164	-0.03 (-0.07 to -0.00)		
F) Cryopreservation	Basic model ^b + cryopreservation ^g		-0.03 (-0.06 to -0.00)		

^aPer 5 years in sample B-D and per year in sample E-F. ^bBasic model includes adjustment for parity, maternal age and country. ^cSmoking (yes/no) ^dBMI: <20, 20-24, 25-29, ≥30 kg/m². ^eAdjusted for maternal age and country. ^fCleavage stage vs blastocyst transfer. ^gFresh vs frozen embryo transfer.

ART: Assisted reproductive technology, RD: Risk difference, CI: Confidence interval, BMI: Body mass index.

Supplemental Table 4. Time trends in placenta previa in pregnancies conceived after assisted reproductive technology (ART) and spontaneous conception. Estimates of time trends are risk differences in percentage points.

Analysis sample	Model	Cases/ Deliveries	RD ^a (95% CI)	Cases/ Deliveries	RD ^a (95% CI)
All pregnancies		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		0.23 (0.13 to 0.34)		0.03 (0.02 to 0.03)
B) BMI & smoking	Basic model ^b + smoking ^c	1,759/ 93,295	0.22 (0.11 to 0.32)	12,492/ 3,424,972	0.03 (0.02 to 0.04)
B) BMI & smoking	Basic model ^b + BMI ^d		0.24 (0.14 to 0.34)		0.03 (0.02 to 0.03)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		0.22 (0.12 to 0.32)		0.03 (0.03 to 0.04)
C) Primiparous	Basic model ^e	1,584/ 99,974	0.25 (0.18 to 0.31)	6,993/ 2,641,775	0.03 (0.02 to 0.03)
D) History of cesarean section	Basic model ^b	847/ 40,421	0.25 (0.10 to 0.38)	11,668/ 3,148,760	0.04 (0.03 to 0.05)
D) History of cesarean section	Basic model ^b + history of cesarean section		0.24 (0.10 to 0.40)		0.04 (0.03 to 0.04)
E) Culture duration	Basic model ^b	986/ 53,230	0.06 (0.00 to 0.10)		
E) Culture duration	Basic model ^b + culture duration ^f		0.03 (-0.02 to 0.08)		
F) Cryopreservation	Basic model ^b	1,993/ 121,987	0.04 (0.03 to 0.05)		
F) Cryopreservation	Basic model ^b + cryopreservation ^f		0.05 (0.04 to 0.06)		
Singletons		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		0.24 (0.13 to 0.35)		0.03 (0.02 to 0.03)
B) BMI & smoking	Basic model ^b + smoking ^c	1,588/ 82,867	0.22 (0.11 to 0.34)	12,302/ 3,380,732	0.03 (0.02 to 0.04)
B) BMI & smoking	Basic model ^b + BMI ^d		0.24 (0.13 to 0.35)		0.03 (0.02 to 0.03)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		0.23 (0.11 to 0.34)		0.03 (0.03 to 0.04)
C) Primiparous	Basic model ^e	1,402/ 85,404	0.22 (0.15 to 0.30)	6,874/ 2,607,276	0.03 (0.02 to 0.03)
D) History of cesarean section	Basic model ^b	771/ 34,972	0.18 (0.03 to 0.33)	11,503/ 3,107,064	0.04 (0.04 to 0.05)
D) History of cesarean section	Basic model ^b + history of cesarean section		0.17 (0.02 to 0.33)		0.04 (0.03 to 0.04)
E) Culture duration	Basic model ^b	930/ 49,285	0.06 (0.00 to 0.11)		
E) Culture duration	Basic model ^b + culture duration ^f		0.03 (-0.02 to 0.08)		
F) Cryopreservation	Basic model ^b	1,787/ 104,085	0.03 (0.02 to 0.05)		
F) Cryopreservation	Basic model ^b + cryopreservation ^f		0.04 (0.03 to 0.06)		
Twins		ART		Spontaneous conception	
B) BMI & smoking	Basic model ^b		0.08 (-0.22 to 0.37)		-0.00 (-0.06 to 0.05)
B) BMI & smoking	Basic model ^b + smoking ^c	170/ 10,240	0.05 (-0.25 to 0.35)	189/ 43,690	0.01 (-0.04 to 0.06)
B) BMI & smoking	Basic model ^b + BMI ^d		0.08 (-0.22 to 0.37)		0.00 (-0.05 to 0.06)
B) BMI & smoking	Basic model ^b + smoking ^c + BMI ^d		0.05 (-0.25 to 0.35)		0.01 (-0.04 to 0.07)
C) Primiparous	Basic model ^e	178/ 14,093	0.29 (0.14 to 0.44)	118/ 33,856	0.03 (-0.01 to 0.08)
D) History of cesarean section	Basic model ^b	75/ 5,360	0.34 (0.04 to 0.65)	164/ 41,196	0.00 (-0.04 to 0.05)

D) History of cesarean section	Basic model ^b + history of cesarean section		0.34 (0.04 to 0.65)		0.00 (-0.05 to 0.05)
E) Culture duration	Basic model ^b	56/ 3,896	0.01 (-0.17 to 0.20)		
E) Culture duration	Basic model ^b + culture duration ^f		0.00 (-0.20 to 0.20)		
F) Cryopreservation	Basic model ^b	202/ 17,164	0.05 (0.02 to 0.07)		
F) Cryopreservation	Basic model ^b + cryopreservation ^g		0.05 (0.02 to 0.08)		

^aPer 5 years in sample B-D and per year in sample E-F. ^bBasic model includes adjustment for parity, maternal age and country. ^cSmoking (yes/no) ^dBMI: <20, 20-24, 25-29, ≥30 kg/m². ^eAdjusted for maternal age and country. ^fCleavage stage vs blastocyst transfer. ^gFresh vs frozen embryo transfer.

ART: Assisted reproductive technology, RD: Risk difference, CI: Confidence interval, BMI: Body mass index.